Nkarta Frames Lupus Plans, Cost Cuts Into A Pleasing Picture For Investors

Stock Rises On NK Cell Updates, Move Into Autoimmune Diseases

 
• By Mandy Jackson
  
Blue growth graph business chart
Nkarta's stock doubled after its recent updates • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip